$RSSS

Research Solutions Targets AI-Driven Growth as High-Margin SaaS Revenue Rises

Research Solutions (NASDAQ:RSSS) is shifting focus to AI-driven growth, launching connector products for AI tools. The company reports rising SaaS revenue with high margins, and expects to double net income. It has about 1,000 corporate customers and a $4B market opportunity. The company has $12M in cash, no debt, and expects to complete remaining earn-out payments by June 2027.

Original reporting
Published Aug 29, 2026, 6:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 29, 2026, 7:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Research Solutions Targets AI-Driven Growth as High-Margin SaaS Revenue Rises — source image
Decision brief

The 30-second read

$RSSSBullishLow
01

Why it matters

The shift could improve gross margins from ~25% to >85% on platform revenue, supporting cash‑flow generation and possible future buybacks or dividends.

02

Market read

First disclosure of AI‑driven SaaS expansion for RSSS, offering a modest trading catalyst.

03

What to watch

Potential regulatory scrutiny over AI‑generated content licensing and the longer sales cycles may dampen near‑term growth.

Relevance 6/10Novelty 6/10Timing: today

Background

Research Solutions (NASDAQ:RSSS) is transitioning from a transaction‑based document‑delivery model to a high‑margin SaaS platform, adding AI connectors to its products.

Company-level read

Ticker impact

$RSSSBullishMedium confidence
Context

Research Solutions disclosed new AI‑connector products, higher‑margin SaaS revenue growth and upcoming high‑value deals, indicating a shift to a higher‑margin business model.

Expected impact

Expect modest price appreciation if the market prices in the higher‑margin SaaS trajectory.

Evidence & confidence

The company reports rising platform ARR and EBITDA, but the information is still early‑stage and depends on execution of large AI‑related deals.

Market effects

Highlights growing demand for AI‑enabled research tools, potentially benefiting other SaaS providers in the scientific publishing space.

U.S. enterprise software market may see incremental demand from research‑intensive firms.

Signals broader trend of AI integration in knowledge‑management platforms worldwide.

Counterpoint

If AI‑connector adoption stalls or security concerns delay deployments, the projected revenue upside could be overstated.

Key entities

  • Olivier

    Company spokesperson discussing AI strategy.

  • Dave Kutil

    Provided financial details on margin mix and EBITDA.

Related articles

$RSSSMed

Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results

Research Solutions (RSSS) reported fiscal Q4 2026 revenue of $12.1M, down from $12.4M YoY. Full-year revenue was $48.3M, slightly below prior year's $49.1M. Net income rose to $2.8M for the year, up from $1.3M. B2B ARR grew 14% YoY to $16.2M, with AI-related ARR up 125% sequentially. Gross margin improved to 53% in Q4 and 51.9% for the year, driven by platform revenue growth.

$RSSSMed

Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results

Research Solutions, Inc. (RSSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results Reports Record Fiscal Year Net Income of $2.8 Million, 14% YoY B2B ARR Increase and ARR of $22.5 Million HENDERSON, Nev., September 9, 2026 — Research Solutions, Inc. (NASDAQ

$ERICMed

Ericsson, Verizon To Deploy AI-native Network Automation

Ericsson (ERIC) and Verizon (VZ) partnered to deploy AI-driven automation in Verizon's radio access network. Verizon plans a nationwide rollout of Ericsson's Intelligent Controller platform, which has shown throughput gains of up to 8.9% downlink and 8% uplink. Verizon will also develop its own rApps. ERIC shares were down 1.31% at $10.94, while VZ shares were up 0.28% at $45.17.

$KAPAMedAI 8/10

In a prostate cancer trial, median time without progression was 17.7 months on two drugs, 2 on one.

Kairos Pharma (KAPA) reported positive interim results from a Phase 2 trial of ENV-105 plus apalutamide in metastatic castration-resistant prostate cancer, showing a median progression-free survival of 17.7 months compared to 2 months with apalutamide alone. The trial will now focus on first-line therapy after enzalutamide. ENV-105 targets CD105, a protein linked to treatment resistance. The company is presenting these findings at the Cancer R&D 2026 conference.

$DELLMed

Why is Dell Technologies stock rallying today?

Dell Technologies (DELL) shares rose 4.6% after a 17% two-day decline, driven by Super Micro Computer's raised revenue guidance and a new AI security partnership with CrowdStrike and NVIDIA. The broader market showed modest gains, with tech and AI infrastructure stocks recovering. Investors await Dell's fiscal Q3 2027 earnings on November 24.

$AMDMedAI 9/10

Samsung’s Next Texas Fab Could Be Almost Entirely for AMD

Samsung's second Texas chip plant, Taylor Fab 2, may be nearly fully utilized by AMD for high-bandwidth memory production, according to Maeil Business Newspaper. The plant, set for 2030, will make logic base dies for AMD, paired with DRAM from Samsung's South Korean fabs. This deal is significant for Samsung's foundry business, competing with TSMC. The plant's 2nm process could also benefit Samsung's Exynos chips for future Galaxy phones.